Veradermics (MANE) Income towards Parent Company (2025 - 2026)
Veradermics' (MANE) quarterly Income towards Parent Company came in at -$27.2 million in Q1 2026, down 119.61% YoY from $138.8 million in Q1 2025, and down 119.61% on a QoQ basis from -$12.4 million in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Income towards Parent Company (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Income towards Parent Company data on file, last reported at -$27.2 million in Q1 2026.
- Quarterly Income towards Parent Company fell 119.61% year-over-year to -$27.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.6 million (changed N/A YoY) and the FY2025 annual result came in at -$70.0 million, down 164.25% from the prior year.
- Income towards Parent Company eased to -$27.2 million in Q1 2026, from -$12.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$12.4 million in Q1 2025 to a low of -$27.2 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.50 Mn |
| Mar 31, 2026 | -27.23 Mn |
| Jun 30, 2025 | -15.65 Mn |
| Mar 31, 2025 | -12.40 Mn |